Skip to main content
OSE Immunotherapeutics logo

OSE Immunotherapeutics — Investor Relations & Filings

Ticker · OSE ISIN · FR0012127173 LEI · 969500HIUWVGY6NZSM05 PA Manufacturing
Open in API
Filings indexed 815 across all filing types
Latest filing 2025-08-20 Board/Management Inform…
Country FR France
Listing PA OSE

About OSE Immunotherapeutics

https://www.ose-immuno.com/en/home/

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.

Recent filings

Filing Released Lang Actions
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Chief Financial Officer (Thomas Gidoin) at OSE Immunotherapeutics. It details his professional background, quotes the CEO and the new CFO, and provides company contact information. This falls squarely under the category of management changes.
2025-08-20 English
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory disclosure required by French law (Article L. 233-8 II of the Commercial Code and Article 223-16 of the AMF General Regulation) regarding the total number of voting rights and shares composing the capital of OSE Immunotherapeutics. This type of filing is a standard regulatory announcement for publicly traded companies in France to keep the market informed of capital structure changes. Since it does not fit into specific categories like 'Share Issue' (as it is a status update, not an announcement of a new issuance) or 'Major Shareholding' (as it is not a notification of a specific shareholder's stake), it falls under the 'Regulatory Filings' category.
2025-08-12 French
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
Regulatory Filings Classification · 100% confidence The document is titled 'OSE Immunotherapeutics Launches Newsletter for Individual Shareholders' and describes the introduction of a new communication channel (a newsletter) aimed at individual investors. It is a press release format, announcing a new informational product rather than releasing financial results (ER), an official regulatory report (10-K, IR), or a formal meeting announcement (AGM-R, DEF 14A). Since it is an announcement about a new communication/investor relations tool, and it doesn't fit the specific categories like Director's Dealing, Capital Change, or Dividend Notice, it falls best under the general 'Regulatory Filings' (RNS) category as a general corporate announcement, or potentially Investor Presentation (IP) if the newsletter content was highly strategic, but given the description as a 'Newsletter' and the format, RNS is the most appropriate fallback for a general corporate update that isn't a core financial filing or specific event material. The document length is moderate (4535 chars), so the RPA rule does not strictly apply, as it is the content itself, not an announcement *of* another report.
2025-07-17 English
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
Regulatory Filings Classification · 85% confidence The document is a press release announcing the launch of a new 'Newsletter for individual investors' by OSE Immunotherapeutics. It details the purpose of the newsletter (communication channel, sharing news, highlighting teams) and provides subscription information. It is not a formal regulatory filing like a 10-K, IR, or ER. It is an announcement about a new communication tool aimed at investors. Since there is no specific category for 'Newsletter Launch Announcement', and it is a general communication piece intended for investors, it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially 'Investor Presentation' (IP) if it were a presentation, but it is explicitly a newsletter launch. Given the options, RNS serves as the best general announcement/communication fallback, although it is not a standard regulatory filing. However, looking closely at the definitions, this is a direct communication piece about investor relations, not a formal report or a standard regulatory filing. Since it is an announcement about a new communication channel, and not the content of a formal report, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, as it doesn't fit ER, IR, IP, or DEF 14A. The document length (4738 chars) is short, but it is the content itself, not an announcement *of* another document, which would trigger RPA.
2025-07-17 French
Bilan semestriel du contrat de liquidité avec Invest Securities
Net Asset Value Classification · 95% confidence The document is a 'Bilan semestriel du contrat de liquidité' (Half-year report on the liquidity contract). This document details the number of shares and cash balance held in a liquidity account managed by a third party (Invest Securities) on behalf of OSE Immunotherapeutics. This type of disclosure is a standard regulatory requirement for companies listed on Euronext to report on their share buyback/liquidity programs. Since it specifically reports on the status of the company's own shares held in a liquidity account, it falls under the category of 'Transaction in Own Shares'.
2025-07-16 French
Half-Year Report on Liquidity Contract with Invest Securities
Transaction in Own Shares Classification · 95% confidence The document is a short announcement (3,643 characters) detailing the status of a liquidity contract (share and cash balances) as of a specific date. It does not constitute a full financial report or a major shareholding notification, but rather a periodic regulatory disclosure regarding the company's share repurchase/liquidity program. Given the nature of the disclosure regarding the liquidity account, it fits best under the 'Transaction in Own Shares' category as it reports on the assets held within the liquidity contract.
2025-07-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.